Jaenisch, Muraru, and Pandey join PharmTech's Cole to discuss FDA's generative AI paper, ARPA-H's SURPASS trials, and AI accountability.
News|Articles|October 21, 2026
Nitrosamine Problems and Industry Solutions: PharmTech Explained
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Advertisement
Advertisement
In April 2026, a generic manufacturer pulled 165,000 more bottles of duloxetine from shelves, the ninth recall of the antidepressant in 2 years. Each was a voluntary Class II action tied to excess N-nitroso-duloxetine, a nitrosamine impurity classified as a probable human carcinogen. The latest episode of PharmTech Explained builds on
Related to this article
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
Advertisement
Advertisement